XML 62 R35.htm IDEA: XBRL DOCUMENT
v3.19.3

COMMITMENTS AND CONTINGENCIES (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract] |
Schedule of Contingent Consideration | A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the nine months ended September 30, 2019 and 2018 is as follows (in thousands):
Nine Months Ended September 30, 2019 | Contingent Consideration Liability Related to Acquisition of Arkis (See Note 2) |  | Contingent Consideration Liability Related to Acquisition of Derma Sciences
| Long-term |  | Long-term
Balance as of January 1, 2019 | $ | — |  |  | $ | 230 |
Additions from acquisition of Arkis | 13,100 |  |  | — |
Balance as of September 30, 2019 | $ | 13,100 |  |  | $ | 230 |
Nine months Ended September 30, 2018 |  | Contingent Considerations Liabilities Related to Acquisition of Derma Sciences |  | Contingent Consideration Liability Related to Acquisition of Confluent Surgical, Inc. |  | Location in Financial Statements
|  | Short-term |  | Long-term |  | Short-term |  |
Balance as of January 1, 2018 |  | $ | 315 |  |  | $ | 1,387 |  |  | $ | 22,478 |  |  |
Transfers from long-term to current portion |  | 1,387 |  |  | (1,387 | ) |  | — |  |  |
Payments |  | (2,000 | ) |  | — |  |  | (19,000 | ) |  |
Loss from change in fair value of contingent consideration liabilities |  | 298 |  |  | 230 |  |  | 1,522 |  |  | Selling, general and administrative
Balance as of September 30, 2018 |  | $ | — |  |  | $ | 230 |  |  | $ | 5,000 |  |  |

X
- References No definition available. + Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258 + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration